Clinical Cancer Research · 2007 · 442 citations · 36 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyImmunoregulationCell-mediated ImmunityCytokines In Tumor ImmunityRegulatory T CellsT Cell BiologyTumor Immune MicroenvironmentTumor-infiltrating LymphocytesCd4 Positive T CellsCd4+ Tumor-infiltrating LymphocytesImmune Suppression MechanismsInterleukin-10 Production By Regulatory T CellsPeripheral Regulatory T CellsTransforming Growth Factor Beta RegulationTransforming Growth Factor Beta-mediated Immune SuppressionTransforming Growth Factor-beta Signaling
PURPOSE: Immunosuppression, including that mediated by CD4(+)CD25(high)Foxp3(+) regulatory T cells (Treg), is a characteristic feature of head and neck squamous cell carcinoma (HNSCC). Tregs with a distinct phenotype in tumor-infiltrating lymphocytes (TIL) contribute to local immune suppression. EXPERIMENTAL DESIGN: The frequency and phenotype of Treg in TIL and/or peripheral blood mononuclear cells (PBMC) in 15 HNSCC patients and PBMC in 15 normal controls were compared. Single-cell sorted CD4(+)CD25(high) T cells were tested for regulatory function by coculture with carboxyfluorescein diacetate succinimidyl ester-labeled and activated autologous CD4(+)CD25(-) responder T cells. Transwell inserts separating Treg from responders and neutralizing interleukin-10 (IL-10) or transforming growth factor-beta1 (TGF-beta1) antibodies were used to evaluate the mechanisms used by Treg to suppress responder cell proliferation. RESULTS: In TIL, CD25(+) cells were enriched in the CD3(+)CD4(+) subset (13 +/- 3%) relative to circulating CD3(+)CD4(+) T cells (3 +/- 0.7%) in HNSCC patients (P < or = 0.01) or normal controls (2 +/- 1.5%; P < or = 0.001). Among the CD3(+)CD4(+) subset, CD25(high) Treg represented 3 +/- 0.5% in TIL, 1 +/- 0.3% in PBMC, and 0.4 +/- 0.2% in normal controls. Tregs in TIL were GITR(+), IL-10(+), and TGF-beta1(+), although circulating Treg up-regulated CD62L and CCR7 but not GITR, IL-10, or TGF-beta1. Treg in TIL mediated stronger suppression (P < or = 0.001) than Treg in PBMC of HNSCC patients. The addition of neutralizing IL-10 and TGF-beta antibodies almost completely abrogated suppression (5 +/- 2.51%). Transwell inserts partly prevented suppression (60 +/- 5% versus 95 +/- 5%). CONCLUSIONS: Suppression in the tumor microenvironment is mediated by a unique subset of Treg, which produce IL-10 and TGF-beta1 and do not require cell-to-cell contact between Treg and responder cells for inhibition.
36
A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
Hervé Groux, Anne O’Garra, Mike Bigler et al. · Nature · 1997 · 3.6K citations
Life Sciences, Immunology, Pathology +12
Helmut Jonuleit, Edgar Schmitt, Michael Stassen et al. · The Journal of Experimental Medicine · 2001 · 1.2K citations · Full text
Megan K. Levings, Romina Sangregorio, Maria-Grazia Roncarolo · The Journal of Experimental Medicine · 2001 · 963 citations · Full text